Skip to main content
PMC home page
International Journal of Molecular Sciences logoLink to International Journal of Molecular Sciences
. 2018 Jun 1;19(6):1644. doi: 10.3390/ijms19061644

Butterbur Leaves Attenuate Memory Impairment and Neuronal Cell Damage in Amyloid Beta-Induced Alzheimer’s Disease Models

Namkwon Kim 1, Jin Gyu Choi 2, Sangsu Park 3, Jong Kil Lee 4,*, Myung Sook Oh 1,5,*
PMCID: PMC6032106  PMID: 29865187

Abstract

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease, and is characterized by the accumulation of amyloid beta (Aβ) as a pathological hallmark. Aβ plays a central role in neuronal degeneration and synaptic dysfunction through the generation of excessive oxidative stress. In the present study, we explored whether leaves of Petasites japonicus (Siebold & Zucc.) Maxim. (PL), called butterbur and traditionally used in folk medicine, show neuroprotective action against Aβ25–35 plaque neurotoxicity in vitro and in vivo. We found that PL protected Aβ25–35 plaque-induced neuronal cell death and intracellular reactive oxygen species generation in HT22 cells by elevating expression levels of phosphorylated cyclic AMP response element-binding protein, heme oxygenase-1, and NAD(P)H quinine dehydrogenase 1. These neuroprotective effects of PL were also observed in Aβ25–35 plaque-injected AD mouse models. Moreover, administration of PL diminished Aβ25–35 plaque-induced synaptic dysfunction and memory impairment in mice. These findings lead us to suggest that PL can protect neurons against Aβ25–35 plaque-induced neurotoxicity and thus may be a potential candidate to regulate the progression of AD.

Keywords: Alzheimer’s disease, butterbur, Petasites japonicus, amyloid beta, memory

1. Introduction

Alzheimer’s disease (AD), an irreversible and degenerative brain disease, is characterized by progressive memory and cognitive dysfunction [1,2]. The hallmarks of AD are senile plaque by excessive accumulation of extracellular amyloid beta (Aβ) and neurofibrillary tangles by hyperphosphorylation of intracellular tau in the brain [3]. Although the exact pathology of AD is not yet clear, a number of studies have shown that Aβ in the brain is the primary cause of the pathogenesis of AD. A correlation between Aβ accumulation and memory impairment in AD patients has also been reported [4,5,6]. Aβ induces the generation of proapoptotic factors such as cytochrome c and caspase-3 by increasing intracellular calcium levels and facilitating the formation of reactive oxygen species (ROS) [7]. Accumulating evidence suggests that increased ROS by Aβ is one of the most important mechanisms involved in the neuronal degeneration, synaptic loss, and memory impairment of AD [8]. Thus, inhibition of Aβ-induced neurotoxicity may provide neuroprotective benefits in AD.

Butterbur, Petasites japonicus (Siebold & Zucc.) Maxim., has been known for various biological activities, including antiallergic, antiinflammatory, and antioxidant effects [9,10,11]. P. japonicus leaf (PL) extract and petaslignolide A, an active compound of PL, have been reported to have neuroprotective effects on oxidative stress induced by kainic acid in mice [12,13]. In addition, kaempferol isolated from P. japonicus stems reduced the damage of neuronal cells against glutamate-induced oxidative stress by regulating antiapoptotic factors (B-cell lymphoma 2), proapoptotic factors (Bax-like BH3 protein and apoptosis-inducing factor), and mitogen-activated protein kinases (p38, extracellular signal-regulated kinase, and c-Jun N-terminal kinase) in mouse hippocampal cells [14]. Park et al. reported that both whole extract of P. japonicus and two isolated compounds, petatewalide B and bakkenolide B, inhibited neuroinflammatory responses in lipopolysaccharide-stimulated BV2 microglia cells via upregulation of AMP-activated protein kinase/nuclear factor erythroid 2-related factor 2 signaling [15,16]. Also, flower buds of P. japonicus inhibited aggregation of bovine serum albumin and lactalbumin as well as Aβ1–42 [17]. However, the neuroprotective effects of PL in Aβ-induced AD in in vitro and in vivo models have not been explored.

Based on these concepts and findings, the present study was designed to determine whether PL has neuroprotective effects against Aβ25–35 plaque-induced neurotoxicity, and if so, how it might lead to beneficial effects in AD. To explore this, we used HT22 cells treated with Aβ25–35 plaque and acutely induced AD mouse models.

2. Results

2.1. Standardization of PL

To determine the active constituents of PL, it was examined by high performance liquid chromatography-mass spectrometry (HPLC-MS) analysis. We observed that PL contains 3,4-dicaffeoylquinic acid (0.02 μg/g), 3,5-dicaffeoylquinic acid (0.15 μg/g), and 4,5-dicaffeoylquinic acid (0.43 μg/g; Figure 1). These compounds were used to standardize the PL in this study. These compounds were shown to have antioxidant effects in previous studies [18,19,20].

Figure 1.

Figure 1

Open in a new tab

Representative HPLC-MS chromatogram of 3,4-dicaffeoylquninic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquninic acid in Petasites japonicus leaf (PL).

2.2. PL Protects Neuronal Cells against Aβ25–35 Plaque Toxicity

We first checked the cytotoxicity of PL in HT22 cells. Treatment with PL at 1, 10, and 100 μg/mL for 24 h did not show toxicity to HT22 cells (Figure 2A). To investigate whether PL protects neuronal cells from Aβ25–35 plaque, HT22 cells were treated with Aβ25–35 plaque in the presence or absence of PL for 24 h. After exposure to Aβ25–35 plaque, cell viability was significantly decreased to 37.69 ± 1.21% compared with the control group, whereas PL at 10 and 100 μg/mL significantly restored cell viability to 50.60 ± 1.08% and 66.61 ± 1.00%, respectively (Figure 2B).

Figure 2.

Figure 2

Open in a new tab

Effect of PL on cell death induced by Aβ25–35 plaque in HT22 cells. HT22 cells were treated with PL (1–100 μg/mL) for 1 h and incubated (A) without or (B) with Aβ25–35 plaque (10 μmol/L) for a further 23 h. Cell viabilities were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay 24 h after sample treatment and are presented as percentage of control. Values are mean ± standard error of the mean. *** p < 0.001 vs. control group, ### p < 0.001 vs. Aβ25–35 plaque group.

2.3. PL Reduces the Accumulation of ROS Induced by Aβ25–35 Plaque via Antioxidant Responses

Oxidative stress occurs when ROS levels exceed the antioxidant capacity of cells [21]. To evaluate the scavenging activity of PL on free radicals, which induce oxidative damage to biomolecules, we performed 2,2-azinobis-(3-ethyl-benzthiazolin-6-sulphonic acid) (ABTS) and 2,2-diphenyl-2-picrylhydrazyl (DPPH) assays. In these two assays, PL showed dose-dependent free radical scavenging activity (Figure 3). The inhibiting concentration (IC50) values of ABTS and DPPH for PL were 38.84 and 35.89 μg/mL, respectively. These data suggest that PL exhibits potential scavenging activities against free radicals compared with Scutellaria baicalensis extract, used as a positive control.

Figure 3.

Figure 3

Open in a new tab

Radical scavenging activity of PL. (A) 2,2-azinobis-(3-ethyl-benzthiazolin-6-sulphonic acid) (ABTS) radical cation and (B) 2,2-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging activities at concentrations of 2–250 μg/mL. SB, Scutellaria baicalensis.

We then investigated whether PL inhibits the increase of Aβ25–35 plaque-induced intracellular ROS levels in HT22 cells. Aβ25–35 plaque significantly increased ROS levels by 145.84 ± 5.23% compared with the control group. As shown in Figure 4A, this increase was reduced by pretreatment with PL in HT22 cells in a concentration-dependent manner (10 μg/mL: 98.01 ± 2.27%; 100 μg/mL: 83.00 ± 4.81%). To explore the underlying mechanism by which PL reduced ROS levels in Aβ25–35 plaque-stimulated HT22 cells, we measured protein and mRNA expression levels of heme oxygenase-1 (HO-1) and NAD(P)H quinine dehydrogenase 1 (NQO1), which have pivotal roles in cellular antioxidant signaling [22,23]. The mRNA expression levels of HO-1 and NQO1 were decreased by Aβ25–35 plaque, but pretreatment with PL significantly ameliorated that effect (Figure 4B,C). In a parallel experiment, we analyzed the protein expression levels of HO-1 and NQO1. As with mRNA expression, PL significantly increased the protein expression levels of HO-1 and NQO1 reduced by Aβ25–35 plaque (Figure 4D,E).

Figure 4.

Figure 4

Figure 4

Open in a new tab

Inhibitory effect of PL on intracellular reactive oxygen species (ROS) generation induced by Aβ25–35 plaque in HT22 cells. Cells were treated with PL (10 and 100 μg/mL) for 1 h and incubated with Aβ (10 μmol/L) for a further 23 h. (A) ROS generation was measured by fluorescence intensity of 2’,7’-dichlorofluorescin (DCF) 24 h after PL treatment and is presented as percentage of control. Cell lysates were assessed by qRT-PCR and Western blot using heme oxygenase-1 (HO-1) and NAD(P)H quinine dehydrogenase 1 (NQO1) antibodies. (B–E) Quantification of (B) mRNA and (D) protein of HO-1 and (C) mRNA and (E) protein of NQO1. The data were normalized to GAPDH or β-actin. Values are mean ± standard error of the mean. * p < 0.05 and *** p < 0.001 vs. control group; # p < 0.05, ## p < 0.01 and ### p < 0.001 vs. Aβ25–35 plaque group.

2.4. PL Increases Phosphorylation of CREB in Aβ25–35 Plaque-Stimulated HT22 Cells and Mice

ROS induced by Aβ regulates the expression of cyclic AMP response element-binding protein (CREB), which is closely related to neuronal survival, synaptic plasticity, memory function, and antioxidant systems [24,25,26]. It has been reported that antioxidant defense systems attenuated ROS-mediated damage of neuronal cells [26]. We evaluated whether PL treatment activates CREB signaling. Aβ25–35 plaque decreased phosphorylation of CREB in HT22 cells compared with the control group. PL at 100 μg/mL significantly reversed this phenomenon (Figure 5A). Next, to confirm the in vitro results, we also investigated expression of pCREB in the dentate gyrus (DG) of Aβ25–35 plaque-injected mice using immunofluorescence analysis. Aβ25–35 plaque-induced decline of pCREB expression was prevented by PL administration (Figure 5B). These findings suggest that PL decreased Aβ25–35 plaque-induced intracellular ROS accumulation via upregulation of pCREB and antioxidant enzymes.

Figure 5.

Figure 5

Open in a new tab

Effect of PL on phosphorylation of cyclic AMP response element-binding protein (CREB) in Aβ25–35 plaque-stimulated HT22 cells and mice. Cells were treated with PL (100 μg/mL) for 1 h and incubated with Aβ (10 μmol/L) for a further 23 h. Cell lysates were assessed by Western blot using pCREB antibody. (A) Quantification of pCREB protein was normalized to β-actin. After stereotaxic injection of Aβ25–35 plaque, mice were treated with vehicle or PL for 17 days; (B) pCREB expression was explored in the dentate gyrus (DG). Scale bar = 100 μm. Values are mean ± standard error of the mean. * p < 0.05 vs. control group; # p < 0.05 vs. Aβ25–35 plaque group. The arrowheads in magnified images point to pCREB/4’,6-diamidino-2-phenylindole (DAPI) double-labeled neurons.

2.5. PL Protects Hippocampal Cells against Aβ25–35 Plaque Toxicity in Mice

Our in vitro data indicate that PL can protect neuronal cells against the oxidative stress induced by Aβ25–35 plaque. To confirm whether PL has neuroprotective effects in the AD mouse model, we performed neuronal nuclei (NeuN) immunohistochemistry in the mouse hippocampus. NeuN is a nuclear protein used as a neuronal marker [27]. The optical density of NeuN in the hippocampal CA3 and DG regions of the Aβ25–35 plaque group (1648.33 ± 135.81 and 3213.15 ± 531.84 OD/mm2, respectively) was significantly lower than that of the sham group. Treatment with PL at 30 mg/kg significantly increased NeuN-positive cells compared with the Aβ25–35 plaque group (Figure 6). These data demonstrate that PL protects neuronal cells from Aβ toxicity in the hippocampus.

Figure 6.

Figure 6

Open in a new tab

Effect of PL on neuronal cell loss in Aβ25–35 plaque-injected mice. After stereotaxic injection of Aβ25–35 plaque, mice were treated with vehicle, PL, or donepezil for 17 days. Neuronal cells were stained with anti-NeuN antibody. The optical density of the NeuN-stained cells was measured in the (A) CA3 and (B) DG; (C) Representative images of NeuN-positive neurons in the CA3 (up) and DG (down) of mice brain. Scale bar = 30 μm. Values are mean ± standard error of the mean. *** p < 0.001 vs. sham group; # p < 0.05 and ## p < 0.01 vs. Aβ25–35 plaque group. Donepezil was used as a positive control.

2.6. PL Inhibits Aβ25–35 Plaque-Induced Synaptotoxicity in Mice

It has been shown that accumulated Aβ causes synaptic degeneration involved in memory function [28,29]. We examined the effect of PL on synaptotoxicity induced by Aβ25–35 plaque. Synaptophysin (SYN) and postsynaptic density protein 95 (PSD-95) as synaptic markers are closely connected with cognitive function, and altering of these markers is important for synaptic connectivity and plasticity [28]. In our data, the immunoreactivity of both SYN and PSD-95 was significantly decreased in the hippocampal CA3 region of the Aβ25–35 plaque group (447.10 ± 42.62 and 726.68 ± 59.99 OD/mm2) compared with the sham group. PL at 30 mg/kg (887.86 ± 105.81 and 1397.81 ± 154.33 OD/mm2) significantly increased the intensity of SYN and PSD-95 immunoreactivity compared with the Aβ25–35 plaque group (Figure 7).

Figure 7.

Figure 7

Open in a new tab

Effect of PL on synaptotoxicity in Aβ25–35 plaque-injected mice. After stereotaxic injection of Aβ25–35 plaque, mice were treated with vehicle, PL, or donepezil for 17 days. Synapses were stained with anti-SYN antibody or anti-PSD-95 antibody. The optical density of the SYN (A) and PSD-95 (B) were measured in the CA3; (C) Representative images of SYN (up) and PSD-95 (down) in the CA3 of mice brain. Scale bar = 30 μm. Values are mean ± standard error of the mean. ** p < 0.01 and *** p < 0.001 vs. sham group; # p < 0.05 vs. Aβ25–35 plaque group. Donepezil was used as a positive control.

2.7. PL Ameliorates Memory Impairment Induced by Aβ25–35 Plaque

To explore the effect of PL on Aβ25–35 plaque-induced cognitive deficits, we performed a novel object recognition test (NORT) and a passive avoidance test (PAT). In the NORT, the Aβ25–35 plaque group (43.25 ± 2.86%) spent less time exploring the novel object than the sham group (76.12 ± 4.89%). The memory index of PL at 30 mg/kg was significantly increased by 66.32 ± 3.26% compared with the Aβ25–35 plaque group (Figure 8A). The Aβ25–35 plaque group also exhibited fear memory impairment (80.45 ± 15.31 s) compared with the sham group (200.95 ± 30.11 s) in the PAT. However, the latency time after treatment with PL at 10 and 30 mg/kg was significantly increased in the test trial (207.91 ± 34.99 and 209.89 ± 28.88 s, respectively; Figure 8B). These data suggest that PL might alleviate memory deficits induced by Aβ25–35 plaque by inhibiting neurodegeneration and synaptic disruption in the mouse hippocampus.

Figure 8.

Figure 8

Open in a new tab

Effect of PL on memory impairment induced by Aβ25–35 plaque in mice, as measured by (A) novel object recognition test (NORT) and (B) passive avoidance test (PAT) (n = 7–8 per group). Values are mean ± standard error of the mean. * p < 0.01 and *** p < 0.001 vs. sham group; # p < 0.05 vs. Aβ25–35 plaque group. Donepezil was used as a positive control.

3. Discussion

In this study, we demonstrated that PL has neuroprotective effects in AD models. PL could prevent hippocampal cell death from Aβ25–35 plaque by regulating ROS generation, CREB phosphorylation, and antioxidant enzymes. Furthermore, PL alleviated memory impairment by protecting neuronal cells and synapses from Aβ25–35 plaque in mice.

Oxidative stress induced by Aβ toxicity plays a key role in the pathogenesis of AD and is involved in intracellular ROS formation and antioxidative system dysfunction [30]. Aβ-induced oxidative stress can also induce the loss of synapses and neuronal cells through inhibition of CREB phosphorylation [31]. It has been reported that phosphorylation of CREB activates HO-1 and NQO1, which protect hippocampal cells against glutamate-induced damage [32]. CREB is a nuclear protein that performs a critical role in cell survival as well as memory formation. CREB can influence memory by inducing neuronal excitability and synaptic modification, because long-term potentiation depends on the depolarization level of postsynaptic neurons [33]. Our results suggest that PL inhibits neuronal cell death by Aβ25–35 plaque-induced ROS by modulating CREB phosphorylation-mediated generation of antioxidant enzymes (HO-1 and NQO1). In accordance with our in vitro results, we confirmed the free radical scavenging effects of PL in ABTS and DPPH assays; IC50 values of PL-treated groups were lower than those of the positive controls. Although the exact compounds within PL evoking neuroprotective effects remain unclear, some previous studies may partly explain our results. It has been reported that 3,4-dicaffeoylquinic acid, 3,5-dicaffeoylquinic acid, and 4,5-dicaffeoylquinic acid, which are standardized compounds of PL in this study, displayed radical scavenging actions in ABTS assays [18]. In addition, 3,4-dicaffeoylquinic acid and 3,5-dicaffeoylquinic acid protected primary cortical neurons from glutamate-induced apoptosis through regulation of calcium influx and ROS levels [19]. 3,5-Dicaffeoylquinic acid also protected neuronal cells against H2O2-induced oxidative stress via inhibition of caspase-3 activation and modulation of glutathione levels [20].

Synaptic connections sculpted by synaptic plasticity are strongly associated with memory formation. SYN is a synaptic vesicle protein involved in Ca2+-mediated neurotransmitter release [28]. PSD-95 is localized in the postsynaptic density of brain neurons and organizes the composition and structure of synaptic proteins [28]. It has been shown that Aβ accelerates synapse failure by axonal and dendritic injury, leading to memory impairment [34,35]. Interestingly, we found that PL inhibited neuronal cell death and synaptic loss in AD mice. Also, PL resulted in amelioration of memory impairment in these mice. Although exact mechanisms need to be further investigated, our findings suggest that PL can reduce Aβ25–35 plaque-mediated AD symptoms by protecting hippocampal neurons and synapses. Similar to our results, 3,5-dicaffeoylquinic acid within PL improved spatial learning and memory in senescence-accelerated prone mice through induction of glycolytic enzyme (phosphoglycerate kinase-1) mRNA expression and ATP production [36]. These compounds may contribute to pharmacological activities of PL on AD.

4. Materials and Methods

4.1. Materials

Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum (FBS), and penicillin-streptomycin (PS) were purchased from Hyclone Laboratories (Logan, UT, USA). Aβ25–35 peptide, dimethylsulfoxide anhydrous (DMSO), mouse anti-SYN, triton X-100, slide mounting medium for histology, paraformaldehyde (PFA), 3,3-diaminobenzidine (DAB), DPPH, ABTS, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), 2,7-dichlorodihydrofluorescein diacetate (DCFH-DA), phosphate buffer (PB), and phosphate buffered saline (PBS, pH 7.4) were purchased from Sigma Aldrich (St. Louis, MO, USA). Rabbit anti-PSD-95 and goat anti-NQO1 were purchased from Abcam (Cambridge, UK). Rabbit anti-HO-1 was purchased from Enzo Life Sciences (Farmingdale, NY, USA). Rabbit anti-phosphorylated CREB (pCREB) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Mouse anti-NeuN was purchased from Millipore (Billerica, MA, USA). Normal goat serum (NGS), avidin-viotin complex (ABC), and biotinylated anti-mouse and anti-rabbit antibodies were purchased from Vector Lab (Burlingame, CA, USA).

4.2. Preparation and Standardization of PL

Fresh PL was purchased from a local market (Yeosu, Korea) and dried in an air dryer at 50 °C for 24 h. The leaves were then boiled with a 20-fold quantity of distilled water at 90 °C for 4 h. The obtained extract was filtered, concentrated, and freeze-dried to yield powder (yield: 25.0%). Next, the powder was mixed with a twofold quantity of 70% ethanol at room temperature for 24 h. Its sediment was freeze-dried to yield powder (yield: 12.7%). The powder was stored at −20 °C for further use.

3,4-Dicaffeoylquninic acid (5 mg), 3,5-dicaffeoylquinic acid (46 mg), and 4,5-dicaffeoylquninic (130 mg) were isolated from PL using a Diaion Hp-20 resin column and Sephadex LH-20 column (Sigma Aldrich). These constituents were purified using a high-performance liquid chromatography-mass spectrometry system (Waters, Milford, MD, USA) under the following conditions: column, ACQUITY UPLC® BEH C18 (1.7 μm, 2.1 mm × 100 mm, Waters); flow rate, 0.25 mL/min. The mobile phase consisted of (A) 0.1% formic acid and (B) acetonitrile. The following gradient elution was used: 0 min, 5% B; 5 min, 5% B; 25 min, 60% B; 30 min, 60% B. The constituents were identified using 1H and 13C nuclear magnetic resonance spectroscopy.

4.3. Preparation of Aβ25–35 Plaque

Aβ25–35 plaque was generated as described in a previous method [37]. Briefly, Aβ25–35 monomer was reconstituted in distilled water to a final concentration of 500 μmol/L. Aliquots were incubated at 37 °C for 3 days to make an amyloid plaque.

4.4. Free Radical Scavenging Assay

4.4.1. ABTS Radical Cation Assay

ABTS solution (7.40 mM) was added to 2.60 mM potassium phosphate in the dark at room temperature 24 h before starting the experiment. Various concentrations of PL (2, 10, 50, and 250 μg/mL) were mixed with 7.40 mM ABTS solution and 2.60 mM potassium phosphate. After incubation at room temperature for 5 min, the absorbance of the mixture was measured at 732 nm using a spectrophotometer. Additionally, the antioxidant activity of PL was expressed as the half-maximal IC50 value. Values were estimated by nonlinear regression using Microsoft Excel (2016, Microsoft, Redmond, WA, USA): ABTS cation scavenging activity (%) = (control − sample)/control × 100.

4.4.2. DPPH Radical Scavenging Assay

Radical scavenging activity was measured by a modified method [38]. Various concentrations of PL (2, 10, 50, and 250 μg/mL) were mixed with 0.20 mM DPPH ethanolic solution (1:1). The absorbance of the mixture was determined at 517 nm using a spectrophotometer. Antioxidant activity of PL was expressed as an IC50 value. Values were estimated by nonlinear regression using Microsoft Excel: DPPH radical scavenging activity (%) = (control − sample + blank)/control × 100.

4.5. Cell Culture and Treatment

Mouse hippocampal HT22 cells were obtained from Insug Kang at Kyung Hee University (Seoul, Korea) and cultured in DMEM supplemented with 10% heat-inactivated FBS and 1% PS in a water-saturated atmosphere of 5% CO2 incubated at 37 °C. The cells were subcultured 3 times a week. All experiments were carried out 18 h after cells had been seeded in 96-well plates and 60 mm dishes at densities of 2 × 103 cells/well and 8 × 104 cells/dish. After cell seeding, various concentrations of PL (1, 10, and 100 μg/mL) were applied to the cells for 24 h with or without 10 μmol/L Aβ25–35 plaque for the last 1 h of treatment.

4.6. Measurement of Cell Viability

Cell viability was determined using MTT assay [39]. Treated cells were incubated with 1 mg/mL MTT for 4 h. The supernatants were discarded, and the cells were dissolved in DMSO. Absorption was measured at 570 nm using a microplate reader (Molecular Devices, San Jose, CA, USA) and expressed as a percentage of the value of the control culture.

4.7. Measurement of Intracellular ROS

Intracellular ROS generation levels were measured using DCFH-DA reagent for fluorometric reaction. DCFH-DA is converted to form the fluorescent product 2′,7′-dichlorofluorescin (DCF) when ROS reacts with DCFH, a nonfluorescent compound. Treated cells were incubated with 20 μM DCFH-DA for 30 min. The fluorescence intensity was measured at 485 nm excitation and 535 nm emission using a fluorescence microplate reader (SpectraMax Gemini EM, Molecular Devices, Sunnyvale, CA, USA).

4.8. Western Blot Analysis

Western blot was carried out according to a previously described method [40]. Cell lysates were separated using 12% SDS-polyacrylamide gel electrophoresis and transferred to Immobilon-P Transfer Membrane (Millipore, Bedford, MA, USA). Membranes were incubated with 5% skim milk in TBST to block nonspecific binding protein and with the primary antibodies (1:2000 dilution of β-actin and HO-1; 1:1000 dilution of NQO1 and pCREB) overnight at 4 °C. Horseradish peroxidase-conjugated secondary antibodies were then incubated for 1 h. Immunoreactive bands were detected using enhanced chemiluminescence detection solution (Bio-Rad Laboratories, Hercules, CA, USA), and ChemiDocTM XRS+ (Bio-Rad Laboratories) was used for visualization. The intensities of the bands were normalized to the β-actin band using Image J (National Institutes of Health, Bethesda, MD, USA).

4.9. qRT-PCR Analysis

mRNA transcription of cytokines was analyzed by qRT-PCR. Total RNA was extracted from HT22 cells using the RNeasy Plus Mini Kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. RNA samples (5 μg) were subjected to cDNA synthesis using an RNA to cDNA EcoDry Premix kit (Takara, Shiga, Japan). cDNA was subjected to qRT-PCR using SYBR Green Mix (Toyobo, Osaka, Japan) and the CFX Connect real-time PCR system (Bio-Rad Laboratories). Primers, synthesized at Cosmo Genetech (Seoul, Korea), were as follows: HO-1: forward, 5′-CAACAAGCAGAACCCAGTCT-3′, reverse, 5′-CTCGTGGAGACGCTTTACAT; NQO1: forward, 5′-AGATCCTGGAAGGATGGAAG, reverse, 5′-CACAGAGAGGCCAAACTTGT; GAPDH: forward, 5′-TGAATACGGCTACAGCAACA-3′, reverse, 5′-AGGCCCCTCCTGTTATTATG.

4.10. Animals

Male ICR mice (6 weeks, 27–30 g) were purchased from Daehan Biolink (Eumseong, Korea). Animals were accommodated at constant temperature (23 ± 1 °C) and humidity (60 ± 10%) and a 12 h light/dark cycle. They were housed and had free access to water and food. Animal treatment and maintenance were carried out in accordance with the Principles of Laboratory Animal Care (National Institutes of Health publication No. 85-23, revised 1985) and the Animal Care and Use Guidelines of Kyung Hee University, Seoul, Korea (approval number: KHUASP(SE)-15-083, 13 October 2015). We administered PL to mice orally for 17 days after intracerebroventricular (ICV) injection of Aβ25–35 plaque. Behavior tests were performed from day 13 to day 16 of PL treatment (Supplementary Figure S1). The operators responsible for the behavioral experimental procedure and data analysis were blinded and unaware of group allocation throughout the experiments.

4.11. Surgery Procedure

Mice were anesthetized and placed in a stereotaxic apparatus (myNeuroLab, St. Louis, MO, USA). Aβ25–35 plaque (15 nmol/L) was delivered by ICV injection, with coordinates −0.7 mm posterior and +1.2 mm lateral from the bregma and −2.0 mm ventral from the skull surface, according to the stereotaxic atlas of mouse brain [41]. The sham-operated mice were injected with the same volume of only saline. The accuracy of stereotaxic injection to the targeted region was monitored in all animals by examination of the needle tract within brain sections.

4.12. Behavior Test

4.12.1. Novel Object Recognition Test

According to the method described previously, NORT was performed on day 13 of PL treatment. The test apparatus consisted of a dark open field box (45 cm × 45 cm × 45 cm). Prior to the test, mice explored the test apparatus without objects for 5 min daily for 5 days. After the habituation period, each mouse was placed into the test box with 2 identical objects and observed for 3 min. The time spent by the animal examining each object (defined as the training session) was measured. Twenty-four hours after the training session, mice were allowed to explore the objects in the test box for 3 min, using one of the training objects as well as a novel object. The time that the animals spent exploring the novel and familiar objects was measured (defined as the test session). The mice were considered to be interested when they were facing, sniffing, or touching the object. A memory index was expressed as percentage of novel object recognition time (time percentage = t-novel object/(t-novel object + t-familiar object) × 100).

4.12.2. Passive Avoidance Test

On day 15 of PL treatment, learning and memory functions were measured using a 2-compartment step-through passive avoidance apparatus according to a previously described method [42]. The box was divided into bright (21 cm × 21 cm × 21 cm) and dark (21 cm × 21 cm × 21 cm) compartments by a guillotine door. The bright room contained a 50 W electric lamp, while the floor of the dark room was composed of 2 mm stainless steel rods spaced 1 cm apart. Treatment was carried out with PL or saline 1 h before the acquisition trial. Mice were then placed in the bright room for the acquisition trial. After 10 s, the door separating the chambers was opened. As soon as the mouse entered the dark room, the guillotine door was closed and an electrical foot shock (0.5 mA) was delivered throughout the grid floor for 3 s. Twenty-four hours after the acquisition trial, the mice were placed in the bright room for a retention trial. The latency time was defined as the time taken for a mouse to enter the dark room after the door opened. The latency time was recorded for up to 300 s.

4.13. Brain Tissue Preparation

At 24 h after the behavioral test, mice were anesthetized and perfused transcardially with 0.05 M PBS, and then fixed with cold 4% PFA in 0.1 M PB. Brains were removed and post-fixed in 0.1 M PB containing 4% PFA overnight at 4 °C. These were then immersed in a solution containing 30% sucrose in PBS for cryoprotection. Serial 30 μm thick coronal sections were cut on a freezing microtome (Leica, Nussloch, Germany) and stored in cryoprotectant (25% ethylene glycol, 25% glycerol, and 0.02 M PB) at 4 °C until use.

4.14. Immunohistochemistry

Brain sections were rinsed in PBS and treated with 1% hydrogen peroxide for 15 min. They were then incubated with mouse anti-NeuN antibody (1:1000 dilution), mouse anti-SYN antibody (1:250 dilution), rabbit anti-PSD-95 antibody (1:500 dilution), or mouse anti-pCREB (1:100 dilution) overnight at 4 °C in the presence of 0.3% triton X-100, 1% NGS, and 1% bovine serum albumin. Next, sections (NeuN, SYN, and PSD-95) were rinsed in PBS and incubated with biotinylated anti-mouse and anti-rabbit IgG (1:250 dilution) for 90 min and with ABC (1:100 dilution) for 60 min at room temperature. Peroxidase activity was visualized using DAB in 0.05 M tris-buffered saline (pH 7.6). After several rinses with PBS, sections were mounted on gelatin-coated slides, dehydrated, and cover-slipped using HistoMount medium. The optical densities of NeuN, SYN, and PSD-95-immunoreactivities in the CA3 or DG of the hippocampus were analyzed with Image J software. Brain sections (pCREB) were incubated with anti-mouse Alexa Fluor 594 (1:1000 dilution) for 60 min and mounted with anti-fade fluorescent medium. To measure the optical densities of NeuN, SYN, PSD-95, and pCREB, the entire region of interest was manually outlined and averaged optical densities were acquired in images with converted 8-bit indexed color. The images were photographed at 200× or 400× magnification using an optical light microscope (Olympus Microscope System BX51; Olympus, Tokyo, Japan) equipped with a 20× objective lens.

4.15. Statistical Analysis

All data were expressed as mean ± standard error of the mean (SEM) using Graph Pad Prism 5.0 (Graph Pad software, San Diego, CA, USA). The results were analyzed statistically by unpaired t-test or one-way analysis of variance followed by Tukey’s post hoc test. A p-value less than 0.05 was considered statistically significant.

5. Conclusions

We first demonstrated the neuroprotective effects of PL in Aβ25–35 plaque-induced AD models. PL protects hippocampal cells against Aβ25–35 plaque toxicity by regulating intracellular ROS levels and CREB-induced activation of antioxidant enzymes in in vitro. Administration of PL ameliorated memory impairment as well as neuronal cell damage and synaptic disruption in Aβ25–35 plaque-infused AD mice. Together, our results suggest that PL could be a useful candidate for slowing progression or preventing onset of AD.

Supplementary Materials

Supplementary materials can be found at http://www.mdpi.com/1422-0067/19/6/1644/s1.

Click here for additional data file. (238.3KB, pdf)

Author Contributions

Conceptualization, N.K.; data curation, J.G.C.; investigation, S.P.; methodology, J.G.C.; supervision, M.S.O.; writing—original draft, N.K.; writing—review and editing, J.K.L. and M.S.O.

Funding

This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through the High Value-Added Food Technology Development Program and funded by the Ministry of Agriculture, Food and Rural Affairs (MAFRA) (1160441-1) and the Business Growth Technology R&D Program of SMBA (S2294686).

Conflicts of Interest

The authors declare no conflict of interest.

References

  • 1.Ewbank D.C. Deaths attributable to Alzheimer’s disease in the United States. Am. J. Public Health. 1999;89:90–92. doi: 10.2105/AJPH.89.1.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Forman M.S., Trojanowski J.Q., Lee V.M. Neurodegenerative diseases: A decade of discoveries paves the way for therapeutic breakthroughs. Nat. Med. 2004;10:1055–1063. doi: 10.1038/nm1113. [DOI] [PubMed] [Google Scholar]
  • 3.Querfurth H.W., LaFerla F.M. Alzheimer’s disease. N. Engl. J. Med. 2010;362:329–344. doi: 10.1056/NEJMra0909142. [DOI] [PubMed] [Google Scholar]
  • 4.Davies C.A., Mann D.M., Sumpter P.Q., Yates P.O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer’s disease. J. Neurol. Sci. 1987;78:151–164. doi: 10.1016/0022-510X(87)90057-8. [DOI] [PubMed] [Google Scholar]
  • 5.Masliah E., Mallory M., Alford M., DeTeresa R., Hansen L.A., McKeel D.W., Jr., Morris J.C. Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease. Neurology. 2001;56:127–129. doi: 10.1212/WNL.56.1.127. [DOI] [PubMed] [Google Scholar]
  • 6.Scheff S.W., Price D.A., Schmitt F.A., DeKosky S.T., Mufson E.J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology. 2007;68:1501–1508. doi: 10.1212/01.wnl.0000260698.46517.8f. [DOI] [PubMed] [Google Scholar]
  • 7.Kadowaki H., Nishitoh H., Urano F., Sadamitsu C., Matsuzawa A., Takeda K., Masutani H., Yodoi J., Urano Y., Nagano T., Ichijo H. Amyloid β induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ. 2005;12:19–24. doi: 10.1038/sj.cdd.4401528. [DOI] [PubMed] [Google Scholar]
  • 8.Kamat P.K., Kalani A., Rai S., Swarnkar S., Tota S., Nath C., Tyagi N. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer’s Disease: Understanding the Therapeutics Strategies. Mol. Neurobiol. 2016;53:648–661. doi: 10.1007/s12035-014-9053-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Park C.H., Kim M.Y., Sok D.E., Kim J.H., Lee J.H., Kim M.R. Butterbur (Petasites japonicus Max.) extract improves lipid profiles and antioxidant activities in monosodium l-glutamate-challenged mice. J. Med. Food. 2010;13:1216–1223. doi: 10.1089/jmf.2009.1380. [DOI] [PubMed] [Google Scholar]
  • 10.Lee K.P., Kang S., Park S.J., Choi Y.W., Lee Y.G., Im D.S. Anti-allergic and anti-inflammatory effects of bakkenolide B isolated from Petasites japonicus leaves. J. Ethnopharmacol. 2013;148:890–894. doi: 10.1016/j.jep.2013.05.037. [DOI] [PubMed] [Google Scholar]
  • 11.Choi Y.W., Lee K.P., Kim J.M., Kang S., Park S.J., Lee J.M., Moon H.R., Jung J.H., Lee Y.G., Im D.S. Petatewalide B, a novel compound from Petasites japonicus with anti-allergic activity. J. Ethnopharmacol. 2016;178:17–24. doi: 10.1016/j.jep.2015.12.010. [DOI] [PubMed] [Google Scholar]
  • 12.Cui H.S., Kim M.R., Sok D.E. Protection by petaslignolide A, a major neuroprotective compound in the butanol extract of Petasites japonicus leaves, against oxidative damage in the brains of mice challenged with kainic acid. J. Agric. Food Chem. 2005;53:8526–8532. doi: 10.1021/jf051595q. [DOI] [PubMed] [Google Scholar]
  • 13.Oh S.H., Sok D.E., Kim M.R. Neuroprotective effects of butterbur and rough aster against kainic Acid-induced oxidative stress in mice. J. Med. Food. 2005;8:169–176. doi: 10.1089/jmf.2005.8.169. [DOI] [PubMed] [Google Scholar]
  • 14.Yang E.J., Kim G.S., Jun M., Song K.S. Kaempferol attenuates the glutamate-induced oxidative stress in mouse-derived hippocampal neuronal HT22 cells. Food Funct. 2014;5:1395–1402. doi: 10.1039/c4fo00068d. [DOI] [PubMed] [Google Scholar]
  • 15.Park S.Y., Choi M.H., Li M., Li K., Park G., Choi Y.W. AMPK/Nrf2 signaling is involved in the anti-neuroinflammatory action of Petatewalide B from Petasites japonicus against lipopolysaccharides in microglia. Immunopharmacol. Immunotoxicol. 2018;40:232–241. doi: 10.1080/08923973.2018.1434791. [DOI] [PubMed] [Google Scholar]
  • 16.Park S.Y., Choi M.H., Park G., Choi Y.W. Petasites japonicus bakkenolide B inhibits lipopolysaccharideinduced proinflammatory cytokines via AMPK/Nrf2 induction in microglia. Int. J. Mol. Med. 2018;41:1683–1692. doi: 10.3892/ijmm.2017.3350. [DOI] [PubMed] [Google Scholar]
  • 17.Okada M., Okada Y. Potential Properties of Plant Sprout Extracts on Amyloid β. Biochem. Res. Int. 2016;2016:9347468. doi: 10.1155/2016/9347468. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Shang Y.F., Kim S.M., Song D.G., Pan C.H., Lee W.J., Um B.H. Isolation and identification of antioxidant compounds from Ligularia fischeri. J. Food Sci. 2010;75:C530-5. doi: 10.1111/j.1750-3841.2010.01714.x. [DOI] [PubMed] [Google Scholar]
  • 19.Kim J.Y., Lee H.K., Hwang B.Y., Kim S., Yoo J.K., Seong Y.H. Neuroprotection of Ilex latifolia and caffeoylquinic acid derivatives against excitotoxic and hypoxic damage of cultured rat cortical neurons. Arch. Pharm. Res. 2012;35:1115–1122. doi: 10.1007/s12272-012-0620-y. [DOI] [PubMed] [Google Scholar]
  • 20.Kim S.S., Park R.Y., Jeon H.J., Kwon Y.S., Chun W. Neuroprotective effects of 3,5-dicaffeoylquinic acid on hydrogen peroxide-induced cell death in SH-SY5Y cells. Phytother. Res. 2005;19:243–245. doi: 10.1002/ptr.1652. [DOI] [PubMed] [Google Scholar]
  • 21.Mates J.M. Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology. 2000;153:83–104. doi: 10.1016/S0300-483X(00)00306-1. [DOI] [PubMed] [Google Scholar]
  • 22.Gozzelino R., Jeney V., Soares M.P. Mechanisms of cell protection by heme oxygenase-1. Annu. Rev. Pharmacol. Toxicol. 2010;50:323–354. doi: 10.1146/annurev.pharmtox.010909.105600. [DOI] [PubMed] [Google Scholar]
  • 23.Dinkova-Kostova A.T., Talalay P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem. Biophys. 2010;501:116–123. doi: 10.1016/j.abb.2010.03.019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Walton M.R., Dragunow I. Is CREB a key to neuronal survival? Trends Neurosci. 2000;23:48–53. doi: 10.1016/S0166-2236(99)01500-3. [DOI] [PubMed] [Google Scholar]
  • 25.Nithianantharajah J., Levis H., Murphy M. Environmental enrichment results in cortical and subcortical changes in levels of synaptophysin and PSD-95 proteins. Neurobiol. Learn. Mem. 2004;81:200–210. doi: 10.1016/j.nlm.2004.02.002. [DOI] [PubMed] [Google Scholar]
  • 26.Shukla V., Mishra S.K., Pant H.C. Oxidative stress in neurodegeneration. Adv. Pharmacol. Sci. 2011;2011:572634. doi: 10.1155/2011/572634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mullen R.J., Buck C.R., Smith A.M. NeuN, a neuronal specific nuclear protein in vertebrates. Development. 1992;116:201–211. doi: 10.1242/dev.116.1.201. [DOI] [PubMed] [Google Scholar]
  • 28.Glantz L.A., Gilmore J.H., Hamer R.M., Lieberman J.A., Jarskog L.F. Synaptophysin and postsynaptic density protein 95 in the human prefrontal cortex from mid-gestation into early adulthood. Neuroscience. 2007;149:582–591. doi: 10.1016/j.neuroscience.2007.06.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Meyer-Luehmann M., Spires-Jones T.L., Prada C., Garcia-Alloza M., de Calignon A., Rozkalne A., Koenigsknecht-Talboo J., Holtzman D.M., Bacskai B.J., Hyman B.T. Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease. Nature. 2008;451:720–724. doi: 10.1038/nature06616. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gella A., Durany N. Oxidative stress in Alzheimer disease. Cell Adhes. Migr. 2009;3:88–93. doi: 10.4161/cam.3.1.7402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Pugazhenthi S., Wang M., Pham S., Sze C.I., Eckman C.B. Downregulation of CREB expression in Alzheimer’s brain and in Aβ-treated rat hippocampal neurons. Mol. Neurodegener. 2011;6:60. doi: 10.1186/1750-1326-6-60. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Park S.Y., Jung W.J., Kang J.S., Kim C.M., Park G., Choi Y.W. Neuroprotective effects of α-iso-cubebene against glutamate-induced damage in the HT22 hippocampal neuronal cell line. Int. J. Mol. Med. 2015;35:525–532. doi: 10.3892/ijmm.2014.2031. [DOI] [PubMed] [Google Scholar]
  • 33.Lisman J., Cooper K., Sehgal M., Silva A.J. Memory formation depends on both synapse-specific modifications of synaptic strength and cell-specific increases in excitability. Nat. Neurosci. 2018;21:309–314. doi: 10.1038/s41593-018-0076-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Coleman P., Federoff H., Kurlan R. A focus on the synapse for neuroprotection in Alzheimer disease and other dementias. Neurology. 2004;63:1155–1162. doi: 10.1212/01.WNL.0000140626.48118.0A. [DOI] [PubMed] [Google Scholar]
  • 35.Spires-Jones T.L., Hyman B.T. The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron. 2014;82:756–771. doi: 10.1016/j.neuron.2014.05.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Han J., Miyamae Y., Shigemori H., Isoda H. Neuroprotective effect of 3,5-di-O-caffeoylquinic acid on SH-SY5Y cells and senescence-accelerated-prone mice 8 through the up-regulation of phosphoglycerate kinase-1. Neuroscience. 2010;169:1039–1045. doi: 10.1016/j.neuroscience.2010.05.049. [DOI] [PubMed] [Google Scholar]
  • 37.Kim H.G., Ju M.S., Park H., Seo Y., Jang Y.P., Hong J., Oh M.S. Evaluation of Samjunghwan, a traditional medicine, for neuroprotection against damage by amyloid-beta in rat cortical neurons. J. Ethnopharmacol. 2010;130:625–630. doi: 10.1016/j.jep.2010.05.040. [DOI] [PubMed] [Google Scholar]
  • 38.Brand-Williams W., Cuvelier M.E., Berset C. Use of a free radical method to evaluate antioxidant activity. LWT Food Sci. Technol. 1995;28:25–30. doi: 10.1016/S0023-6438(95)80008-5. [DOI] [Google Scholar]
  • 39.Ryu O., Park B.K., Bang M., Cho K.S., Lee S.H., Gonzales E.L.T., Yang S.M., Kim S., Eun P.H., Lee J.Y., et al. Effects of Several Cosmetic Preservatives on ROS-Dependent Apoptosis of Rat Neural Progenitor Cells. Biomol. Ther. (Seoul) 2018 doi: 10.4062/biomolther.2017.221. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Kim H.G., Oh M.S. Memory-enhancing effect of Mori Fructus via induction of nerve growth factor. Br. J. Nutr. 2013;110:86–94. doi: 10.1017/S0007114512004710. [DOI] [PubMed] [Google Scholar]
  • 41.Paxinos G., Franklin K. Paxinos and Franklin’s the Mouse Brain in Stereotaxic Coordinates. 4th ed. Volume 360 Academic Press; Cambridge, MA, USA: 2012. [Google Scholar]
  • 42.Weon J.B., Jung Y.S., Ma C.J. Cognitive-Enhancing Effect of Dianthus superbus var. Longicalycinus on Scopolamine-Induced Memory Impairment in Mice. Biomol. Ther. (Seoul) 2016;24:298–304. doi: 10.4062/biomolther.2015.083. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Click here for additional data file. (238.3KB, pdf)

Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES